Clinical trial WIZARD
Zanubrutinib in patients with Waldenström Macroglobulinemia, a multicenter observational real-world data study In Belgium (WIZARD / BGB-3111-MA-BE-403-WM)
| Cancers | |
|---|---|
| Organ | Blood |
| Trial status | Trial closed |
| Trial type |
Prospective observational study
|
| Academic trial | Non |
| Sponsor | BeiGene |
| BECT Identifier | B6702025000010 |
| Inclusion criteria | Adult patients; Diagnosed with WM; Receiving or having received zanubrutinib treatment, eligible for reimbursement according to guidelines of RIZIV/INAMI |
| Last update |